Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | VEGFA | P15692 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6204006 | 0.93 | CHRNA7 (0.48) | CHRNA7CHRNB2CHRNA4VEGFAEGLN1 | |
| SCHEMBL6202242 | 0.92 | CHRNA7 (0.55) | CHRNA7CHRNB2CHRNA4VEGFAEGLN1 | |
| SCHEMBL6201717 | 0.87 | CHRNA7 (0.52) | CHRNA7CHRNB2CHRNA4VEGFAEGLN1 | |
| SCHEMBL6202173 | 0.85 | CHRNA7 (0.50) | CHRNA7CHRNB2CHRNA4VEGFAEGLN1 | |
| SCHEMBL6202706 | 0.80 | ACHE (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19ACHE | |
| SCHEMBL6202179 | 0.78 | CHRNA7 (0.65) | CHRNA7ACHECHRNB4CHRNA3 | |
| SCHEMBL7146756 | 0.77 | VEGFA (0.63) | VEGFAEGLN1LMNAHTTCYP1A2 | |
| SCHEMBL6201186 | 0.72 | HRH3 (0.43) | CHRNA7CYP1A2CYP3A4CYP2C19KMT2A | |
| SCHEMBL5750271 | 0.72 | FUCA1 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19ACHE | |
| SCHEMBL21793950 | 0.72 | FUCA1 (0.56) | CYP1A2CYP3A4CYP2D6CYP2C19ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | NEUROSEARCH A/S (DK) | 2004-07-29 | — | — | US | claimed |
| EP-1397365-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NeuroSearch A/S (DK) | 2004-03-17 | — | — | EP | claimed |
| WO-2002096911-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH A/S (DK) | 2002-12-05 | — | — | WO | claimed |
| EP-1397365-B1 | HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH AS (DK) | 2005-02-16 | — | — | EP | disclosed |
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | NEUROSEARCH A/S (DK) | 2004-07-29 | — | — | US | disclosed |
| EP-1397365-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NeuroSearch A/S (DK) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002096911-A1 | NOVEL HETEROARYL-DIAZABICYCLO-ALKANES AS CNS-MODULATORS | NEUROSEARCH A/S (DK) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147505-A1 | Novel heteroaryl-diazabicyclo alkanes as cns-modulators | CHRNA3, CHRNA5, CHRNA2 | CHRNA7 5/4885CHRNB2 9/4885CHRNA4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.